abstract Population aging is rapidly accelerating worldwide; however, longer life expectancy is not the only public health goal. Indeed, extended lifetime involves maintaining function and the capacity of living independently. Sarcopenia and physical frailty are both highly relevant entities with regards to functionality and autonomy of older adults. The concepts and definitions of frailty and sarcopenia have largely been revised over the years. Sarcopenia is an age-related progressive and generalized loss of skeletal muscle mass and strength. On the other hand, frailty is a state of increased vulnerability to stressors, responsible for exposing the older person to enhanced risk of adverse outcomes. Physical frailty and sarcopenia substantially overlap and several adverse outcomes of frailty are likely mediated by sarcopenia. Indeed, the concepts of sarcopenia and physical frailty can be perceived as related to the same target organ (i.e., skeletal muscle) and it may be possible to combine them into a unique definition. The biological background of such a close relationship needs to be explored and clarified as it can potentially provide novel and pivotal insights for the assessment and treatment of these conditions in old age. The aim of this paper is to indicate and discuss possible biological markers to be considered in the framing of physical frailty and sarcopenia.
background
A healthy musculoskeletal system is necessary for physical functioning. A decrease of skeletal muscle mass is a universal consequence of aging with a broad range of functional and metabolic consequences [1] . Skeletal muscle affects a wide spectrum of vital processes that are often inadequately appreciated [2] . Clearly, skeletal muscle is responsible for movement and loss of muscle mass and quality may result in weakness and reduced mobility; however, skeletal muscle is also the largest reserve of proteins in the body. During periods of stress, under-nutrition, or starvation, it provides a continuous supply of amino acids in order to support the protein synthesis for vital organs.
Skeletal muscle represents the primary site of glucose disposal, as well. A reduction of muscle mass may cause metabolic dysregulation, especially in patients with insulin resistance and type 2 diabetes. In addition, skeletal muscle is the major energy consumer and contributor to basal metabolic rate in the body. Loss of muscle represents the primary cause of age-associated reduced basal metabolic rate and decreased energy needs [3] .
The age-associated loss of skeletal muscle mass, function, and quality is commonly known as "sarcopenia" [4] [5] [6] [7] . Sarcopenia (derived from Greek sarx for flesh and penia for loss) is a term coined by Rosenberg to describe one of the most noticeable changes occurring with aging [8] . It has been defined as the "progressive loss of muscle mass and strength with a risk of adverse outcomes such as disability, poor quality of life and death" by the Special Interest Group of the European Sarcopenia Working Group in 2010 [9] . The term is used specifically to denote loss of muscle mass and strength associated with aging and distinguishes muscle loss due to aging from other causes, such as immobility or neurological damage. Sarcopenia is recognized as a geriatric syndrome and a key public health issue. Starting at the age of 30 years, individuals lose 1-2% of muscle per year, and by the age of 80 years, 30% of muscle mass is lost [10, 11] .
The prevalence of low muscle mass is estimated to be between 10 and 25% depending on the studied population and methods applied.
In octogenarians the prevalence increases up to 50% [9] . Reduced muscle function is independently associated with increased risk of functional impairment, falls, disability and mortality in older subjects [12] .
Under normal circumstances, muscle homeostasis is maintained as a delicate balance between new muscle cell formation, hypertrophy, and protein loss. This balance is coordinated by the central nervous, endocrine, and immune systems. Behavioral factors (i.e., nutrition and physical activity) may also substantially modify these interactions. health outcomes [13] . All experts unanimously agree on the theory of frailty and the need to push forward its study, thus promoting the implementation of the syndrome in clinics and research. However, frailty cannot be limited to a physical domain; psychological, cognitive, emotional, social and spiritual factors contribute to frailty and need to be taken into account in its definition. Physical frailty characterizes the unique core condition between sarcopenia and frailty [1] . Research on physical frailty is far more advanced than research on other aspects of frailty. A phenotypic approach to physical frailty has been introduced in clinical practice [14] . An alternative model of accumulation of deficits has also been used for measuring frailty in elderly people [15, 16] . None of these approaches seems to yield similar results in clinical practice [17] . Nevertheless, there is an overall agreement about the key role that physical function plays in the determination of the status of extreme vulnerability [18] [19] [20] .
A careful examination of concepts of sarcopenia and physical frailty shows that they share many common points [1] . In fact, several 
elevated inflammatory markers associated with lower muscle mass and strength
In older age, a low-grade inflammatory state characterized by increased concentrations of cytokines and acute phase proteins is common [22, 23] . TNF-α, IL-1β, IL-6, and IL-18, and C-reactive protein (CRP) and fibrinogen are among the cytokines and acute phase proteins that have been frequently studied in describing such chronic inflammatory states [24] . This phenomenon, also called "inflammaging, "
results from an imbalance between pro-and anti-inflammatory networks [25] . Muscle mass and strength are inversely associated with plasma concentrations of IL-6 and TNF-α in well-functioning older men and women [26] [27] [28] , which is only partially explained by decline in muscle strength and slowed walking speed The levels of these damaged macromolecules and lipids increase with age [31, 32] .
Protein carbonyls are known markers of oxidative stress and accumulate with aging [33] . Protein carbonylation leads to cellular dysfunction and a decline in tissue function and is involved in the pathogenesis of sarcopenia [34] . Serum protein carbonyls are independently associated with grip strength [35] .
Advanced glycation end products (AGEs), bioactive compounds that are formed by nonenzymatic glycation of proteins, lipids, and DNA, play a role in the pathogenesis of sarcopenia and physical frailty [36] . Elevated serum AGEs are associated with poor muscle strength [37] .
serum creatinine and urinary creatinine excretion as a marker of muscle mass
Creatine is a naturally occurring nitrogencontaining compound found in the diet, primarily in red meat and seafood [38] . The majority of creatine is stored in skeletal muscle as phosphocreatine (PCr), a high-energy phosphate involved in the rapid resynthesis of adenosine triphosphate (ATP) during intense muscle contraction [38] . Aging may have a negative impact on high-energy phosphate metabolism [39] [40] [41] .
Creatine is the precursor of creatinine. In the steady-state and with stable kidney function, creatinine is usually produced at a relatively constant rate by the body depending on the absolute amount of muscle mass [42] .
Creatinine is filtered out of the blood by the glomeruli (and is excreted to a smaller extent in the proximal tubules of the kidney). Since there is little to no tubular reabsorption of creatinine, its renal clearance is often used to estimate glomerular filtration rate. Under stable kidney function, the serum or plasma concentration of serum creatinine can also reflect skeletal muscle mass, if its non-musclemass-dependent variations (such as due to renal filtration or meat intake) can be accurately accounted for [42] .
A new biological technique to estimate muscle mass has been developed recently by using a dose of creatine labelled with a nonradioactive tracer (deuterium). The isotope, enclosed in a gel capsule is ingested, and a urine sample collected several days later is used to estimate deuterated creatine by mass spectroscopy. The measured dilution space is strongly correlated with total body skeletal muscle mass measured with MRI [43] .
To the best of our knowledge, the relationship between serum or urinary creatinine excretion and muscle strength has not been demonstrated. However, several studies provided evidence for the effects of creatine supplementation on muscle strength [44, 45] .
endocrine function
Decline in muscle mass and parallel decline of muscle function are attributed to a progressive shift from anabolic to catabolic metabolism with a reduced capacity for synthesizing new proteins and repairing muscle damage [46] .
The defect in muscle protein homeostasis may be related to changes in circulating levels of hormones.
The age-associated decline in the production of dehydroepiandrosterone sulfate (DHEAS) is an important determinant of reduced muscle mass and strength in older persons [47] . There is evidence that sex hormones (testosterone, estrogens, and DHEAS), whose levels decrease with age, exert an important role in the agerelated onset of sarcopenia [48] . DHEAS may affect muscle performance. The skeletal muscle is able to convert DHEA into active androgens and estrogens, and to stimulate insulin-like growth factor-1 (IGF-1), which is important for muscle growth and recovery [49] . The maintenance of adult muscle depends on satellite cell activation, proliferation, survival, and differentiation, all of which can also be stimulated by testosterone [50, 51] . The effects of testosterone on muscle can be categorized as anabolic, anti-catabolic, and potentially antiinflammatory [52, 53] .
It has been proposed that testosterone stimulates skeletal muscle protein synthesis, improve recycling of intracellular amino acids, and promote the activity of motor neurons [52] .
However, the proposed effects of testosterone on muscle protein degradation are not straightforward. It appears that short-term testosterone administration does not change the breakdown rate of muscle proteins, whereas treatment for several months decreases muscle protein breakdown [52] . Testosterone promotes commitment of pluripotent stem cells to myogenic lineage but inhibits their differentiation into adipocytes via an androgen receptor-mediated pathway, suggesting the rationale for its well-known effects on the reduction in body fat mass and the increase in fat-free mass and insulin sensitivity [54] .
The link between vitamin D and skeletal muscle health has been well-described in clinical studies [55] . There is a broad range Skeletal muscle is a primary tissue responsible for insulin-mediated glucose disposal; thus, low muscle mass may cause reduced insulinmediated glucose disposal. However, type II muscle fibers, which are less responsive to the metabolic actions of insulin [60] , are lost to a greater extent than type I fibers in age-related muscle atrophy [61] . Moreover, some studies have shown that insulin resistance precedes the development of frailty [62] [63] [64] [65] . 
n-terminal procollagen peptides: measure of muscle fibrosis
Type III collagen in soft connective tissues, such as muscle and skin, is synthesized from larger procollagen III molecules carrying peptide extensions at both N-and C-terminal ends [70] [71] [72] . The N-and C-terminal extensions of procollagen III are removed by specific proteinases during the final stages of collagen synthesis, and released into the circulation in stoichiometric amounts [72] . Procollagen type III N-terminal peptide (P3NP), a product of this proteolytic cleavage during collagen synthesis in connective tissue, can be measured in the human serum, and its circulating concentrations have been described in children, healthy adults, acromegalic subjects, and athletes [73] [74] [75] [76] [77] . P3NP levels vary in response to exercise, testosterone, and growth hormone (GH) [75, [78] [79] [80] [81] [82] , and could represent useful markers of GH doping in sports [75, 76, [80] [81] [82] [83] [84] [85] . Plasma concentrations of P3NP represent an interesting marker of skeletal muscle remodeling. Indeed, serum P3NP concentrations reflect lean body mass and appendicular skeletal muscle mass [86] .
overexpression of myostatin leads to muscle atrophy
Myostatin is a member of the transforming growth factor-b superfamily and is known to be a negative regulator of skeletal muscle myogenesis and functions as an inhibitor of muscle growth [87] [88] [89] . Myostatin-deficient mice have increased muscle mass, whereas overexpression of myostatin leads to muscle atrophy [88, 90] . Although alterations in myostatin expression and activity in the context of aging are not fully understood, aging is associated with upregulated myostatin expression in humans [91] . Thus, older myostatin null mice exhibit resistance to the sarcopenic phenotype [92] [93] [94] and neutralize antibodies to myostatin, leading to an increase in muscle mass and improved measures of muscle performance, including grip strength [95] [96] [97] . he also received a research grant from Pfizer.
